DelSite Biotechnologies, Carrington’s wholly owned subsidiary, is developing GelSite polymer. The patent specifically covers the in-situ gelation (gelling in place) powder technology based on GelSite polymer. GelVac, the company’s nasal powder platform developed based on this technology, is being developed for nasal delivery of vaccines and therapeutics.
Carlton Turner, CEO of Carrington, said: “The GelSite polymer is naturally derived and produced under cGMP with high purity, and requires no organic solvent use for production of the finished product. Eurasian countries are fast-developing economies and are obvious choices for obtaining patent protection.”